This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 7, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) posts their first commercial sale and shipment of Active Pharmaceutical Ingredient (API) grade Strontium-82 to a North American pharmaceutical company. Manhattan Isotope Technology (MIT), LLC, a wholly owned subsidiary of Position Corporation, completed the processing, production and shipment of their API grade strontium-82, which was delivered this week. The API was produced from target material received from one of its foreign collaborators for target irradiation.
Strontium-82, API, is used exclusively to manufacture rubidium-82 generators and is the most widely accepted Positron Emission Tomography (PET) agent utilized in myocardial perfusion imaging.
"I and my team at
MIT, have been developing our isotope production business for many years. This API shipment is a culmination of our company's expertise, research & development efforts, dedication to our isotope program and the efficiencies of
MIT's Sr-82 production facility," said
Jason Kitten, President of
MIT and Positron's Director of Radiopharmaceutical & Radioisotope Production. "Positron's commitment to Rb-82 based cardiac PET continues by addressing the single largest factor limiting its growth, Strontium-82 production. By building upon the current production base and increasing capacity, Positron will bring diversity and confidence to Sr-82 supply, thus providing further assurance that this technology will be a dependable, reliable modality for the nuclear cardiology community. The building blocks of Positron's vertical integration model for cardiac PET now includes Sr-82 API production and with this asset secured we've achieved a key milestone in our end-to-end solution's strategy."
About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiology—providing an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation